KYMR Kymera Therapeutics, Inc.
Price Chart
Executive Summary
Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, showing disease-modifying activity comparable or superior to approved therapies in multiple lupus models. The Phase 1 healthy volunteer trial is ongoing with data expected in 2H26. This is a positive pipeline update for a mid-stage biotech, but preclinical data alone does not guarantee clinical success.
Actionable Insight
Monitor for Phase 1 healthy volunteer data in 2H26, which will be the first clinical read on IRF5 degradation and safety. A positive readout could significantly de-risk the program and drive upside. Until then, the stock may trade on pipeline sentiment and broader biotech sector trends.
Key Facts
- KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models.
- Data presented at EULAR (June 3-6, 2026) and FOCIS (June 9-12, 2026) meetings.
- KT-579 Phase 1 healthy volunteer trial is ongoing; data expected in second half of 2026.
- KT-579 is a first-in-class oral degrader of IRF5, a genetically validated transcription factor.
- Preclinical activity shown in lupus, rheumatoid arthritis, and inflammatory bowel disease models.
- No adverse effects observed in preclinical safety studies at all doses tested.
Financial Impact
No financial data provided; preclinical update with no revenue or earnings impact. Market cap is $6.1B.
Risk Factors
- Preclinical results may not translate to clinical efficacy or safety in humans.
- Phase 1 data is still months away (2H26); no near-term catalyst.
- Competition from existing lupus therapies (biologics, small molecules) and other IRF5-targeting approaches.
- Kymera is a clinical-stage company with no approved products; reliance on pipeline success.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3307932 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Press Release
| $82.96 awaiting T+5 | awaiting T+5 | — | $86.21 (+3.91%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $82.43 awaiting T+5 | awaiting T+5 | — | $86.21 (+4.59%) |
|
Jun 11, 2026
3d ago
|
Institutional Cluster
| $79.19 awaiting T+5 | awaiting T+5 | — | $86.21 (+8.86%) |
|
Jun 8, 2026
6d ago
|
Press Release
| $73.80 awaiting T+5 | awaiting T+5 | — | $86.21 (+16.81%) |
|
May 26, 2026
19d ago
|
144
| $81.70 $73.21 | ▼ −10.39% | ▼ −10.86% | $86.21 (+5.51%) |
|
May 15, 2026
4w ago
|
Press Release
| $82.21 $78.89 | ▼ −4.04% | ▼ −5.00% | $86.21 (+4.86%) |
|
May 11, 2026
4w ago
|
144
| $83.55 $79.67 | ▼ −4.64% | ▼ −4.72% | $86.21 (+3.18%) |
|
Apr 23, 2026
7w ago
|
Press Release
| $87.17 $81.51 | ▼ −6.49% | ▼ −7.97% | $86.21 (−1.11%) |
|
Apr 15, 2026
8w ago
|
144
| $86.14 $87.17 | ▲ +1.20% | ▲ +0.21% | $86.21 (+0.08%) |
|
Apr 15, 2026
8w ago
|
144
| $86.14 $87.17 | ▲ +1.20% | ▲ +0.21% | $86.21 (+0.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access